The renin-angiotensin-aldosterone system (RAAS) blockade is unequivocally established as the first and foremost clinically beneficial strategy in post-myocardial infarction (MI) and heart failure (HF) therapies [1]. The gene discussed is REN; the disease is myocardial infarction.